The abstract is read at the publisher; the summary is JClub's.
In human left ventricular myofibrils carrying HCM β-myosin G716R, relaxation kinetics are slower than in donor hearts, and mavacamten fails to reverse this slowing.
- Why it matters: Mutation-specific sarcomeric effects and how they shape response to the myosin inhibitor mavacamten remain unclear for HCM patients.
- What they did: Myofibrils were isolated from HCM-patient myocardium and healthy donor hearts, and isometric force and force-kinetic parameters were measured with mavacamten across different activation and relaxation conditions, including incomplete relaxation to mimic residual diastolic calcium.
- The result: Patient myofibrils showed similar isometric forces but slower maximum force generation and especially relaxation; mavacamten’s inhibition was less efficient in patient samples, did not restore full relaxation, and further worsened impairment at partial relaxation.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.